Drugs / MTS105
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06689540 | Nov 2024 → Dec 2025 overdue | hepatocellular carcinoma | Shen Lin | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MTS105 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06689540 ↗ |
| Modality | Messenger RNA (mRNA) | “MTS105 (mRNA-LNP)” NCT06689540 ↗ |
| Route | Intravenous | “intravenous injection of MTS105” NCT06689540 ↗ |